+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

World Erectile Dysfunction Drugs Market - Opportunities and Forecasts, 2019 - 2026

  • ID: 3773035
  • Report
  • September 2019
  • Region: Global
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Apricus Biosciences
  • Bayer Ag
  • Eli Lilly & Co
  • Meda Pharmaceuticals
  • Pfizer
  • Vivus Inc
  • MORE

Erectile dysfunction is also termed as impotence and it is characterized by incapability to build up or sustain a penile erection during sexual intercourse. An Erection of penis involves hydraulic effect resulting from entry and retention of blood into spongy bodies within penis. Sexual arousal is responsible for initiation of this process which is signalized by impulse mechanism from brain to penile nerves. The causes of erectile dysfunction involve side effects of drugs, Cavernosal disorders, Neurogenic disorders, Aging, Psychological causes, Multiple sclerosis and Diabetes, and Lifestyle modifications. Pin-point analysis of global erectile dysfunction drugs market focuses on various aspects of market such as, market trends, market drivers, restrains and opportunities. Competitive landscape section focuses on key leaders within global erectile dysfunction drugs market and their major growth strategies. Deep-dive assessment of segments identifies the potential segment which would act as guide to strategist.

The demand for erectile dysfunction therapeutics is highly increasing due to high incidence of chronic diseases including neurogenic disorders, hypertension, diabetes and psychological disorders. Additionally, increasing aged population, patient education and awareness are some of the factors which also fuel the growth of this market. Despite of increasing demand for erectile dysfunction drugs, this market is going to experience a decline in forecast period due to patent expiration of major brands. On contrary, it will provide the key opportunity for generic manufacturers to enter the market. Amongst erectile dysfunction drug users, there is high prevalence of sexually transmitted diseases (STDs) and it could restrain the growth of this market. Generic drugs are the promising opportunity for this market. Moreover, novel drug delivery techniques can also potentiate the market growth.

Global Erectile Dysfunction Drugs Market by Therapeutics

The global erectile dysfunction drugs market by therapeutics is segmented into two categories such as, existing drugs and pipeline drugs. Existing drugs includes the major drug brands namely, Viagra, Levitra/Staxyn, Cialis, Zydena, Helleva, Stendra/Spedra Avanafil and Mvix. Viagra was the blockbuster drug by Pfizer which has generated large revenue for the company. Levitra and Cialis are the major competitor for Viagra and these two brands has also captured a potential market share. Owing to the patent expiration of these major brands during forecast period, market is going to experience a decline in total revenue for erectile dysfunction drugs.

Global Erectile Dysfunction Drugs Market by Geography

Geographically, global erectile dysfunction drugs market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America dominates the global erectile dysfunction drugs market and it is expected to show the same results during forecast period due to the presence of Cialis and Viagra in U.S. market. Patent expiration of these brands outside the U.S. markets, would increase the influx of generics with cheaper prices.

Competitive Landscape

The key players within global erectile dysfunction drugs market include Pfizer, Bayer AG, Eli Lilly & Co., Dong-A Pharmaceutical Co. Ltd, Vivus, Inc., Meda Pharmaceuticals and Apricus Biosciences. Competitors are focusing on novel product manufacturing which will show faster onset of action with minimal side effects as compared to existing therapies. Due to patent expiration of major brands in near future, would increase the competition for generic drugs with cheaper prices.

High Level Analysis

The comprehensive analysis of global erectile dysfunction drugs market provides the overview of the market and its key concerns. Market dynamics covers market drivers, restrains and opportunities within global erectile dysfunction drugs market and helps to understand market behaviour in simple way.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Apricus Biosciences
  • Bayer Ag
  • Eli Lilly & Co
  • Meda Pharmaceuticals
  • Pfizer
  • Vivus Inc
  • MORE

CHAPTER 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY MARKET SEGMENTS
1.3. KEY BENEFITS
1.4. RESEARCH METHODOLOGY
1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

CHAPTER 3: MARKET LANDSCAPE
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3. PORTER'S FIVE FORCES ANALYSIS
3.3.1.Bargaining power of suppliers
3.3.2.Threat of new entrants
3.3.3.Threat of substitutes
3.3.4.Competitive rivalry
3.3.5.Bargaining power among buyers
3.4. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING
3.4.1. Market share analysis/top player positioning 2018
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4: ERECTILE DYSFUNCTION DRUGS MARKET BY DRUGS
4.1. OVERVIEW
4.2. SILDENAFIL
4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market Size and Forecast by region,
4.2.3.Market share analysis, by country
4.3. VARDENAFI
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market Size and Forecast by region,
4.3.3.Market share analysis, by country
4.4. TADALAFIL
4.4.1.Key market trends, growth factors and opportunities
4.4.2.Market Size and Forecast by region,
4.4.3.Market share analysis, by country
4.5. UDENAFIL
4.5.1.Key market trends, growth factors and opportunities
4.5.2.Market Size and Forecast by region,
4.5.3.Market share analysis, by country
4.6. LODENAFI
4.6.1.Key market trends, growth factors and opportunities
4.6.2.Market Size and Forecast by region,
4.6.3.Market share analysis, by country
4.7. STENDRA SPEDRA
4.7.1.Key market trends, growth factors and opportunities
4.7.2.Market Size and Forecast by region,
4.7.3.Market share analysis, by country
4.8. MIRODENAFIL
4.8.1.Key market trends, growth factors and opportunities
4.8.2.Market Size and Forecast by region,
4.8.3.Market share analysis, by country
4.9. APOMORPHINE
4.9.1.Key market trends, growth factors and opportunities
4.9.2.Market Size and Forecast by region,
4.9.3.Market share analysis, by country
4.10. ALPROSTADIL
4.10.1.Key market trends, growth factors and opportunities
4.10.2.Market Size and Forecast by region,
4.10.3.Market share analysis, by country
4.11. TOPIGLAN
4.11.1.Key market trends, growth factors and opportunities
4.11.2.Market Size and Forecast by region,
4.11.3.Market share analysis, by country

CHAPTER 5: ERECTILE DYSFUNCTION DRUGS MARKET BY REGION
5.1. OVERVIEW
5.2. NORTH AMERICA
5.2.1.Key market trends and opportunities
5.2.2.Market size and forecast by drugs
5.2.3.Market size and forecast by Country
5.2.4.U.S. Erectile Dysfunction Drugs Market
5.2.4.1.Market size and forecast by drugs
5.2.5. Canada Erectile Dysfunction Drugs Market
5.2.5.1.Market size and forecast by drugs
5.2.6. Mexico Erectile Dysfunction Drugs Market
5.2.6.1.Market size and forecast by drugs
5.3. EUROPE
5.3.1.Key market trends and opportunities
5.3.2.Market size and forecast by drugs
5.3.3.Market size and forecast by Country
5.3.4.Germany Erectile Dysfunction Drugs Market
5.3.4.1.Market size and forecast by drugs
5.3.5. France Erectile Dysfunction Drugs Market
5.3.5.1.Market size and forecast by drugs
5.3.6. UK Erectile Dysfunction Drugs Market
5.3.6.1.Market size and forecast by drugs
5.3.7. Italy Erectile Dysfunction Drugs Market
5.3.7.1.Market size and forecast by drugs
5.3.8. Spain Erectile Dysfunction Drugs Market
5.3.8.1.Market size and forecast by drugs
5.3.9. Rest of Europe Erectile Dysfunction Drugs Market
5.3.9.1.Market size and forecast by drugs
5.4. ASIA PACIFIC
5.4.1.Key market trends and opportunities
5.4.2.Market size and forecast by drugs
5.4.3.Market size and forecast by Country
5.4.4.Japan Erectile Dysfunction Drugs Market
5.4.4.1.Market size and forecast by drugs
5.4.5. China Erectile Dysfunction Drugs Market
5.4.5.1.Market size and forecast by drugs
5.4.6. India Erectile Dysfunction Drugs Market
5.4.6.1.Market size and forecast by drugs
5.4.7. Australia Erectile Dysfunction Drugs Market
5.4.7.1.Market size and forecast by drugs
5.4.8. Rest of Asia-Pacific Erectile Dysfunction Drugs Market
5.4.8.1.Market size and forecast by drugs
5.5. LAMEA
5.5.1.Key market trends and opportunities
5.5.2.Market size and forecast by drugs
5.5.3.Market size and forecast by Country
5.5.4.Brazil Erectile Dysfunction Drugs Market
5.5.4.1.Market size and forecast by drugs
5.5.5. Saudi Arabia Erectile Dysfunction Drugs Market
5.5.5.1.Market size and forecast by drugs
5.5.6. South Africa Erectile Dysfunction Drugs Market
5.5.6.1.Market size and forecast by drugs
5.5.7. Rest of LAMEA Erectile Dysfunction Drugs Market
5.5.7.1.Market size and forecast by drugs

CHAPTER 6: COMPANY PROFILES
6.1. PFIZER
6.1.1. Company overview
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2. BAYER AG
6.2.1. Company overview
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. ELI LILLY & CO
6.3.1. Company overview
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. DONG/A PHARMACEUTICAL CO LTD
6.4.1. Company overview
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5. VIVUS INC
6.5.1. Company overview
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. MEDA PHARMACEUTICALS
6.6.1. Company overview
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. APRICUS BIOSCIENCES
6.7.1. Company overview
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. COMPANY 8
6.8.1. Company overview
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. COMPANY 9
6.9.1. Company overview
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. COMPANY 10
6.10.1. Company overview
6.10.2. Business performance
6.10.3. Key strategic moves and developments

LIST OF TABLES
Table 1. Global Erectile Dysfunction Drugs Market, By Drugs 2018-2026 ($Million)
Table 2. Erectile Dysfunction Drugs Market For Sildenafil, By Region, 2018-2026 ($Million)
Table 3. Erectile Dysfunction Drugs Market For Vardenafi, By Region, 2018-2026 ($Million)
Table 4. Erectile Dysfunction Drugs Market For Tadalafil, By Region 2018-2026 ($Million)
Table 5. Erectile Dysfunction Drugs Market For Udenafil, By Region 2018-2026 ($Million)
Table 6. Erectile Dysfunction Drugs Market For Lodenafi, By Region 2018-2026 ($Million)
Table 7. Erectile Dysfunction Drugs Market For Stendra Spedra, By Region 2018-2026 ($Million)
Table 8. Erectile Dysfunction Drugs Market For Mirodenafil, By Region 2018-2026 ($Million)
Table 9. Erectile Dysfunction Drugs Market For Apomorphine, By Region 2018-2026 ($Million)
Table 10. Erectile Dysfunction Drugs Market For Alprostadil, By Region 2018-2026 ($Million)
Table 11. Erectile Dysfunction Drugs Market For Topiglan, By Region 2018-2026 ($Million)
Table 12. Erectile Dysfunction Drugs Market For, By Region, ,2018-2026 ($Million)
Table 13. North America Erectile Dysfunction Drugs, By Drugs 2018-2026 ($Million)
Table 14. North America Erectile Dysfunction Drugs, By Region 2018-2026 ($Million)
Table 15. Europe Erectile Dysfunction Drugs, By Drugs 2018-2026 ($Million)
Table 16. Europe Erectile Dysfunction Drugs, By Region 2018-2026 ($Million)
Table 17. Asia Pacific Erectile Dysfunction Drugs, By Drugs 2018-2026 ($Million)
Table 18. Asia Pacific Erectile Dysfunction Drugs, By Region 2018-2026 ($Million)
Table 19. Lamea Erectile Dysfunction Drugs, By Drugs 2018-2026 ($Million)
Table 20. Lamea Erectile Dysfunction Drugs, By Region 2018-2026 ($Million)
Table 21. Pfizer: Company Snapshot
Table 22. Pfizer: Operating Segments
Table 23. Bayer Ag: Company Snapshot
Table 24. Bayer Ag: Operating Segments
Table 25. Eli Lilly And Co: Company Snapshot
Table 26. Eli Lilly And Co: Operating Segments
Table 27. Dong A Pharmaceutical Co Ltd: Company Snapshot
Table 28. Dong A Pharmaceutical Co Ltd: Operating Segments
Table 29. Vivus Inc: Company Snapshot
Table 30. Vivus Inc: Operating Segments
Table 31. Meda Pharmaceuticals: Company Snapshot
Table 32. Meda Pharmaceuticals: Operating Segments
Table 33. Apricus Biosciences: Company Snapshot
Table 34. Apricus Biosciences: Operating Segments
Table 35. Company 8: Company Snapshot
Table 36. Company 8: Operating Segments
Table 37. Company 9: Company Snapshot
Table 38. Company 9: Operating Segments
Table 39. Company 10: Company Snapshot
Table 40. Company 10: Operating Segments

LIST OF FIGURES
Figure 1. Global Erectile Dysfunction Drugs Market Segmentation
Figure 2. Top Investment Pocket
Figure 3. Top Winning Strategies (%)
Figure 4. Erectile Dysfunction Drugs Market For Sildenafil, 2018-2026 ($Million)
Figure 5. Erectile Dysfunction Drugs Market For Vardenafi, 2018-2026 ($Million)
Figure 6. Erectile Dysfunction Drugs Market For Tadalafil, 2018-2026 ($Million)
Figure 7. Erectile Dysfunction Drugs Market For Udenafil, 2018-2026 ($Million)
Figure 8. Erectile Dysfunction Drugs Market For Lodenafi, 2018-2026 ($Million)
Figure 9. Erectile Dysfunction Drugs Market For Stendra Spedra, 2018-2026 ($Million)
Figure 10. Erectile Dysfunction Drugs Market For Mirodenafil, 2018-2026 ($Million)
Figure 11. Erectile Dysfunction Drugs Market For Apomorphine, 2018-2026 ($Million)
Figure 12. Erectile Dysfunction Drugs Market For Alprostadil, 2018-2026 ($Million)
Figure 13. Erectile Dysfunction Drugs Market For Topiglan, 2018-2026 ($Million)
Figure 14. Global Erectile Dysfunction Drugs, By Region, 2015 (%)
Figure 15. U.S. Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 16. Canada Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 17. Mexico Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 18. Germany Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 19. France Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 20. Uk Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 21. Italy Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 22. Spain Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 23. Rest Of Europe Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 24. Japan Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 25. China Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 26. India Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 27. Australia Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 28. Rest Of Asia-Pacific Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 29. Brazil Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 30. Saudi Arabia Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 31. South Africa Erectile Dysfunction Drugs Market, 2018-2026 ($Million)
Figure 32. Rest Of Lamea Erectile Dysfunction Drugs Market, 2018-2026 ($Million)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer
  • Bayer Ag
  • Eli Lilly & Co
  • Dong/A Pharmaceutical Co Ltd
  • Vivus Inc
  • Meda Pharmaceuticals
  • Apricus Biosciences
Note: Product cover images may vary from those shown
5 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll